NDC 0781-7227-06 - BUPRENORPHINE AND NALOXONE
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 0781-7227
- Requested NDC
- 0781-7227-06
- Package NDCs from labels
- 0781-7227-06, 0781-7227-64
- Manufacturer
- Indivior Inc.
- Effective date
- 2021-04-19
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| BUPRENORPHINE AND NALOXONE - Indivior Inc. | Indivior Inc. | 2021-04-19 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0781-7227-06 | EA - Each | 0781-7227 | 783255b0-babb-4a3c-9798-8594e4b0f49b | 1 | 2019-05-02 |
| 0781-7227-64 | EA - Each | 0781-7227 | 12805401-872a-4c9b-b648-4feb63c335d6 | 1 | 2019-03-12 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Unit Dose Solutions, Inc. | 4b301ad7-ac0e-f849-e063-6394a90a27d5 | 2026-02-19 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine | BUPRENORPHINE | Sun Pharmaceutical Industries, Inc. | 9fd1f18f-0b0f-4059-b603-19ecbf0ed63a | 2026-02-11 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | REMEDYREPACK INC. | 68df290c-d776-4cfc-9565-332eb56c4723 | 2026-02-10 | Warnings, Adverse reactions | F850569PQR |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Sun Pharmaceutical Industries, Inc. | 91b68606-05de-4586-ae31-07e8cc9160cf | 2026-02-10 | Warnings, Adverse reactions | 56W8MW3EN1 |
| naloxone hydrochloride | NALOXONE HYDROCHLORIDE | Lifestar Pharma LLC | aef6719c-cd71-46ee-b7b1-1806b939bf3e | 2026-02-09 | Warnings, Adverse reactions | F850569PQR |
| BUPRENORPHINE | BUPRENORPHINE | A-S Medication Solutions | bfb02ea5-22f2-432e-afc8-f1dbe2ea0614 | 2026-02-06 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Actavis Pharma, Inc. | 6cccf229-9611-4b6f-8f1b-acc8ff1ed3f8 | 2026-02-06 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine HCl and Naloxone HCl | BUPRENORPHINE AND NALOXONE | Amneal Pharmaceuticals LLC | 17b63f10-c9df-44be-80fa-6f1c305583b8 | 2026-02-02 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Additive Formula 3 | DEXTROSE MONOHYDRATE, TRISODIUM CITRATE DIHYDRATE, SODIUM CHLORIDE, SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE, CITRIC ACID MONOHYDRATE, AND ADENINE | Terumo BCT, Ltd | 9a5247a1-cc05-442d-b2d0-950f887f03c2 | 2026-01-30 | Warnings, Adverse reactions | 2968PHW8QP |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Camber Pharmaceuticals, Inc. | 221195e4-de08-414c-af08-a611a74789de | 2026-01-30 | Warnings, Adverse reactions | F850569PQR 56W8MW3EN1 |
| Sodium Citrate and Citric Acid | SODIUM CITRATE AND CITRIC ACID MONOHYDRATE | Atlantic Biologicals Corp. | 42d837ae-2578-46df-92d2-24774964aaad | 2026-01-28 | Adverse reactions | 1Q73Q2JULR |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Camber Pharmaceuticals, Inc. | 5ab2d4e4-3c8c-413a-b147-23eafbde313a | 2026-01-28 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine | BUPRENORPHINE | Hikma Pharmaceuticals USA Inc. | 1bf8b35a-b769-465c-a2f8-099868dfcd2f | 2026-01-24 | Warnings, Adverse reactions | 56W8MW3EN1 |
| BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Redpharm Drug | 44f2e26f-4586-5204-e063-6394a90a47d5 | 2026-01-23 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Buprenorphine HCl | BUPRENORPHINE HCL | Camber Pharmaceuticals, Inc. | b52cea0e-688f-4beb-bf7d-f228b81dbd23 | 2026-01-23 | Warnings, Adverse reactions | 56W8MW3EN1 |
| SWISS BLEU Relief-Calm Antimicrobial Skin Cream | LACTOBACILLUS FERMENT LYSATE, LEONTOPODIUM ALPINUM, CALENDULA OFFICINALIS FLOWER EXTRACT, EVENING PRIMROSE FLOWER EXTRACT, CITRIC ACID | Nanjing Hongruixing Biological Technology Co., Ltd | 487d3c2c-ce28-f7a1-e063-6294a90a5ec6 | 2026-01-16 | Warnings | 2968PHW8QP |
| Buprenorphine and Naloxone | BUPRENORPHINE AND NALOXONE | Mylan Pharmaceuticals Inc. | 557d8d4d-8751-431c-b18e-9d5cf23fc579 | 2026-01-15 | Warnings, Adverse reactions | 56W8MW3EN1 |
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | AvKARE | 1766a7f1-d301-945f-e063-6294a90ac6f4 | 2026-01-14 | Warnings | F850569PQR |
| RiVive | NALOXONE HYDROCHLORIDE | Harm Reduction Therapeutics, Inc. | 1c4f1b9d-1c70-4666-a90e-2f5d2c670d4d | 2026-01-13 | Warnings | F850569PQR |
| Naloxone Hydrochloride | NALOXONE HYDROCHLORIDE | Sina Health Inc | 2879294f-9af9-459e-e063-6394a90a0820 | 2026-01-12 | Warnings, Adverse reactions | F850569PQR |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.